Incyte (INCY)
(Delayed Data from NSDQ)
$64.47 USD
+0.05 (0.08%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $64.45 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
INCY 64.47 +0.05(0.08%)
Will INCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INCY
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
Qiagen (QGEN) Expected to Beat Earnings Estimates: Should You Buy?
Other News for INCY
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Incyte Corporation: Balancing Robust Jakafi Sales Against Strategic Pipeline Shifts
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Terns Pharmaceuticals (TERN) and Stryker (SYK)
Incyte’s Strong Product Performance and Growth Trajectory Merit a Buy Rating
Incyte price target raised by $5 at RBC Capital, here's why